Dr.RaviCardio said:The GIP arm is doing real work rather than padding the label.
I read this differently from Dr.RaviCardio, on substance rather than tone. The "tirzepatide is simply better" summary irritates me. It is better on mean weight loss, and the cardiovascular outcome evidence is far thinner than semaglutide's. If the reason for treating is cardiovascular risk rather than weight, the evidence base points the other way.
One concrete data point for the thread. Give anything pharmacological four weeks before you judge it, and give anything measured weekly a four-point rolling average before you call it a trend.
I would rather be corrected than agreed with, if it comes to it.
Dr.MetabolicMD said:The "tirzepatide is simply better" summary irritates me.
There is a second half to this that has not been said yet. It is worth asking what the claim would look like if it were false. If nothing would look different, it is not a claim about the world and no amount of discussion will settle it.
PeptideDetective — Independent Peptide Analytics
Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.
View ResultsOne thing that is still open after hans_munich’s answer:
Whether anyone has held 10mg long term rather than climbing, and what happened over the following year?
Reporting back.
Update: the eight-week restart pattern people described is exactly what happened. I nearly abandoned it at week five.